Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy

Cancer Research and Treatment : Official Journal of Korean Cancer Association
Ya-Ping ZhangJian-Yong Li

Abstract

Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a rare subtype of non-Hodgkin lymphoma, and asparaginase-based regimens are the best first-line treatments. Data on the role of specific circulating lymphocyte subsets in the progression of ENKTL are limited. The aim of this study was to investigate the clinical correlation and distribution of circulating absolute CD4+ T-cell counts (ACD4Cs) in ENKTL. We retrospectively searched medical records for 70 newly diagnosed ENKTL patients treated with pegaspargase-based regimens. Comparison of ACD4Cs as a continuous parameter in different groups was calculated. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS). Stage III/IV, B symptoms, elevated lactate dehydrogenase, monocytopenia, high-intermediate and high risk International Prognostic Index (IPI) and Korean Prognostic Index (KPI), high risk Prognostic Index of Natural Killer Lymphoma (PINK), and lower lymphocytes were significantly associated with low ACD4C at diagnosis. With a median follow-up time of 32 months, patients who had an ACD4C < 0.30×109/L had a worse OS. Median OS was 11 months and median PFS was 5 months in the low A...Continue Reading

References

Nov 10, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert L CampDavid L Rimm
Dec 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeeyun LeeWon Seog Kim
Sep 19, 2007·American Journal of Clinical Pathology·Pin-Pen HsiehChung-Che Chang
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul SalamaBarry Iacopetta
Jun 23, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W Y KimC-W Kim
Oct 24, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SuzukiUNKNOWN NK-cell Tumor Study Group
Jul 3, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J J HuangZ M Li
Jan 26, 2011·Histopathology·Sarah E Coupland
Dec 10, 2013·Seminars in Cancer Biology·Philippe Gaulard, Laurence de Leval
Nov 5, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Liang WangYue Lu
Sep 1, 2015·Journal of Leukocyte Biology·Frederik Wein, Ralf Küppers
Nov 18, 2015·American Journal of Clinical Pathology·Chen ChangKung-Chao Chang
Jun 25, 2016·British Journal of Haematology·Yngvild Nuvin BlakerErlend Bremertun Smeland
Oct 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lu HeWei Xu

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Software Mentioned

tile

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.